



Universiteit
Leiden
The Netherlands

A multivariate genome-wide association study of psycho-cardiometabolic multimorbidity

Baltramonaityte, V.; Pingault, J.B.; Cecil, C.A.M.; Choudhary, P.; Jaervelin, M.R.; Penninx, B.W.J.H.; ... ; EarlyCause Consortium

Citation

Baltramonaityte, V., Pingault, J. B., Cecil, C. A. M., Choudhary, P., Jaervelin, M. R., Penninx, B. W. J. H., ... Walton, E. (2023). A multivariate genome-wide association study of psycho-cardiometabolic multimorbidity. *Plos Genetics*, 19(6). doi:10.1371/journal.pgen.1010508

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3714421>

Note: To cite this publication please use the final published version (if applicable).

RESEARCH ARTICLE

A multivariate genome-wide association study of psycho-cardiometabolic multimorbidity

Vilte Baltramonaityte¹, Jean-Baptiste Pingault^{2,3}, Charlotte A. M. Cecil^{3,4,5}, Priyanka Choudhary⁶, Marjo-Riitta Järvelin^{6,7}, Brenda W. J. H. Penninx⁸, Janine Felix^{9,10}, Sylvain Sebert⁶, Yuri Milaneschi⁸, Esther Walton^{1*}, on behalf of the EarlyCause Consortium[†]

1 Department of Psychology, University of Bath, Bath, United Kingdom, **2** Department of Clinical, Educational, and Health Psychology, University College London, London, United Kingdom, **3** Department of Child and Adolescent Psychiatry/Psychology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands, **4** Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands, **5** Molecular Epidemiology, Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands, **6** Research Unit of Population Health, University of Oulu, Oulu, Finland, **7** Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom, **8** Department of Psychiatry, Amsterdam Public Health and Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands, **9** The Generation R Study Group, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands, **10** Department of Pediatrics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands

[†] Membership of the EarlyCause Consortium is available here <https://earlycause.europe-science.eu/partners>.
* E.Walton@bath.ac.uk



OPEN ACCESS

Citation: Baltramonaityte V, Pingault J-B, Cecil CAM, Choudhary P, Järvelin M-R, Penninx BWJH, et al. (2023) A multivariate genome-wide association study of psycho-cardiometabolic multimorbidity. *PLoS Genet* 19(6): e1010508. <https://doi.org/10.1371/journal.pgen.1010508>

Editor: Heather J. Cordell, Newcastle University, UNITED KINGDOM

Received: November 3, 2022

Accepted: June 12, 2023

Published: June 30, 2023

Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: <https://doi.org/10.1371/journal.pgen.1010508>

Copyright: © 2023 Baltramonaityte et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: To access summary statistics for psycho-cardiometabolic multimorbidity, a data transfer agreement is required with 23andMe ([dataset](https://23andme.com)).

Abstract

Coronary artery disease (CAD), type 2 diabetes (T2D) and depression are among the leading causes of chronic morbidity and mortality worldwide. Epidemiological studies indicate a substantial degree of multimorbidity, which may be explained by shared genetic influences. However, research exploring the presence of pleiotropic variants and genes common to CAD, T2D and depression is lacking. The present study aimed to identify genetic variants with effects on cross-trait liability to psycho-cardiometabolic diseases. We used genomic structural equation modelling to perform a multivariate genome-wide association study of multimorbidity ($N_{\text{effective}} = 562,507$), using summary statistics from univariate genome-wide association studies for CAD, T2D and major depression. CAD was moderately genetically correlated with T2D ($r_g = 0.39$, $P = 2e-34$) and weakly correlated with depression ($r_g = 0.13$, $P = 3e-6$). Depression was weakly correlated with T2D ($r_g = 0.15$, $P = 4e-15$). The latent multimorbidity factor explained the largest proportion of variance in T2D (45%), followed by CAD (35%) and depression (5%). We identified 11 independent SNPs associated with multimorbidity and 18 putative multimorbidity-associated genes. We observed enrichment in immune and inflammatory pathways. A greater polygenic risk score for multimorbidity in the UK Biobank ($N = 306,734$) was associated with the co-occurrence of CAD, T2D and depression (OR per standard deviation = 1.91, 95% CI = 1.74–2.10, relative to the healthy group), validating this latent multimorbidity factor. Mendelian randomization analyses suggested potentially causal effects of BMI, body fat percentage, LDL cholesterol, total cholesterol, fasting insulin, income, insomnia,

request@23andMe.com) before making a request to the University of Bath Research Data Archive (<https://doi.org/10.15125/BATH-01179>). Further information regarding access to 23andMe is available at: <https://research.23andme.com/collaborate/>. Summary statistics for the top 10,000 SNPs generated during this study are available from the University of Bath Research Data Archive: <https://doi.org/10.15125/BATH-01179>. Summary statistics for coronary artery disease can be obtained from: <http://www.cardiogramplusc4d.org>. Summary statistics for type 2 diabetes can be obtained from: <http://diagram-consortium.org/downloads.html>. To access summary statistics for depression, a data transfer agreement is required from 23andMe (dataset-request@23andMe.com) before a request is made to David Howard (D.Howard@ed.ac.uk), as described in: <https://www.nature.com/articles/s41593-018-0326-7>. UK Biobank data can be accessed via an application process outlined here: <https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access>. Code underlying our analyses can be found on GitHub: <https://github.com/VilteBaltra/Psycho-cardiometabolic-multimorbidity>.

Funding: This project has received funding from the European Union's Horizon 2020 research and innovation programme under Grant Agreement No 848158 (EarlyCause). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors declare no competing interests.

and childhood maltreatment. These findings advance our understanding of multimorbidity suggesting common genetic pathways.

Author summary

While observational research has shown a substantial degree of overlap between depression, coronary artery disease and type 2 diabetes, few studies have attempted to identify genetic variants associated with multimorbidity between these conditions. Here, we explore the shared genetic architecture of depression, coronary artery disease and type 2 diabetes (i.e., psycho-cardiometabolic diseases) and examine common genetic variants associated with the co-occurrence of these conditions. Employing a novel method for performing multivariate genome-wide association studies, we show that there are 11 independent genetic variants across nine distinct genomic risk loci associated with psycho-cardiometabolic multimorbidity. We observe enrichment in immune and inflammation-related pathways and identify 18 multimorbidity-associated genes. We show that the polygenic risk score developed based on our multimorbidity genome-wide association study is predictive of the co-occurrence of depression, coronary artery disease and type 2 diabetes in an independent sample. Lastly, we identify eight potentially causal risk factors for multimorbidity. These results advance our understanding of the shared genetic influences in psycho-cardiometabolic diseases.

Introduction

Depression, coronary artery disease (CAD) and type 2 diabetes (T2D) are important public health issues. Whilst each of these chronic disorders alone represent a major global burden, multimorbidity between them presents an additional challenge for healthcare systems [1–3]. Epidemiological studies suggest that individuals with depression have an 80–90% greater risk of cardiovascular morbidity and mortality [4] and a 32–60% higher risk of T2D [5,6] than individuals without depression. The reverse association has also been observed, with approximately 40% of people with CAD and 18–28% of people with diabetes either meeting the criteria for depression or experiencing depressive symptoms [7,8]. Notably, life expectancy in individuals with a diagnosis of depression is reduced [9], which may be partially accounted for by the co-occurrence with physical health diseases [10,11]. This emphasizes the importance of understanding the mechanisms through which mental and physical diseases may co-occur.

The relationship between depression, CAD and T2D may be attributed in part to shared lifestyle and other risk factors such as lack of physical activity [12,13], unhealthy diet [14,15], increased body mass index (BMI) [16–18], altered hypothalamic-pituitary-adrenal axis [19,20], inflammation [21–23] and childhood trauma [24]. For instance, BMI and inflammation have been causally linked to all three disorders in Mendelian randomization studies [25–30], albeit with some conflicting findings [31–33]. However, in several meta-analyses, estimates of the CAD-depression and T2D-depression relationship were similar before and after adjustment for major sociodemographic and lifestyle indicators [5,34–36], suggesting that these indicators do not entirely explain the association. Another plausible explanation for multimorbidity between these conditions is the presence of shared genetic aetiology (i.e., pleiotropic genes) that function as a hub linking these disorders [2]. In line with this, twin and family studies reveal moderate genetic correlations between depression and CAD (42%) [37], and depression and T2D (up to 25%) [38]. However, recent studies based on genome-wide

association data and polygenic risk scores provide conflicting evidence [39–41], with only some studies observing significant positive genetic correlations among the above mentioned traits [42–44]. The genetic overlap between CAD and T2D was more consistent, with multiple studies reporting a significant positive genetic correlation [42,45,46].

Despite many studies investigating the genetic overlap between depression, cardiovascular and metabolic diseases [e.g., 47], the latent genetic factor structure across all three diseases has not been explored. Additionally, research exploring the presence of pleiotropic variants and genes that are common to depression, CAD, and T2D is lacking. Characterizing multivariate genetic associations with psycho-cardiometabolic diseases (where *psycho* stands for depression, *cardio* for CAD and *metabolic* for T2D) and understanding the biological mechanisms that contribute to multimorbidity between these conditions is important. It would allow us to examine causal risk factors for multimorbidity (e.g., by providing genetic instruments for Mendelian randomization analysis) and help to identify potentially engageable treatment targets.

Accordingly, the aims of this study were to: (1) model the shared genetic architecture of depression, CAD and T2D with a latent multimorbidity factor; (2) identify genetic variants associated with multimorbidity; (3) perform functional gene mapping to determine if the prioritised genes are enriched in specific tissues or biological pathways; and (4) validate a polygenic risk score for multimorbidity within an independent sample.

Methods

Ethics statement

This research was conducted using the UK Biobank resource, application number 65769. The UK Biobank study was conducted under generic approval from the National Health Service (NHS) Research Ethics Service. The study protocol used by 23andMe was approved by an external Association for Accreditation of Human Research Protection Programs (AAHRPP)-accredited institutional review board. All cohorts contributing to the present study obtained written informed consent from all participants. Additionally, ethical approval for the present study was obtained from the University of Bath (PREC: 20–195).

GWAS selection

First, we identified the largest univariate genome-wide association meta-analyses available to date from individuals of predominantly European ancestry for three distinct phenotypes: major depression [44], CAD [48], and T2D [42] (Table 1; S1 Appendix methods section). We avoided using genome-wide association studies (GWASs) with mixed ancestry groups (i.e., > 25% non-European ancestry individuals), as they may bias results from genetic factor analysis [49]. As a second step, we selected GWASs that do not include the UK Biobank (UKBB) cohort (i.e., Scott et al. [50] for T2D and Howard et al. [44] for depression with UKBB removed), as we planned to use this cohort as an independent replication sample for polygenic risk score (PRS) analysis. For detailed characteristics of the input populations and the sources of data see S1 Table. For a flowchart of all our analyses see Fig A in S1 Appendix.

Single-trait heritability, genetic correlations, and factor analysis

We used linkage disequilibrium (LD) score regression within Genomic structural equation modelling (Genomic SEM, version 0.0.5) [49] to estimate the heritability of depression, CAD and T2D, as well as the genetic correlations among the traits. For quality control steps, see S1 Appendix methods section. Subsequently, Genomic SEM was used to perform a genetic

Table 1. A list of Contributing Genome-Wide Association Studies.

Phenotype	Used in	GWAS	Year	Cases	Controls
CAD	Discovery GWAS for Genomic SEM	Nikpay et al. [48]	2015	60,801	123,504
	Discovery GWAS for PRS	Nikpay et al. [48]	2015	60,801	123,504
T2D	Discovery GWAS for Genomic SEM	Mahajan et al. [42]	2018	74,124	824,006
	Discovery GWAS for PRS	Scott et al. [50]	2017	26,676	132,532
MD	Discovery GWAS for Genomic SEM	Howard et al. [44]	2019	246,363	561,190
	Discovery GWAS for PRS	Howard et al. [44] (no UKBB)	2019	140,045	378,325

Univariate GWASs contributing to the multivariate GWAS of psycho-cardiometabolic multimorbidity. All summary statistics are based on individuals of European ancestry, apart from Nikpay et al. [48], which also includes individuals from mixed ancestry groups (with 77% being European). Summary statistics used to construct the PRS exclude the UK Biobank cohort. GWAS, genome-wide association study; PRS, polygenic risk score; UKBB, UK Biobank.

<https://doi.org/10.1371/journal.pgen.1010508.t001>

factor analysis using diagonally weighted least squares estimation. To estimate the shared variance between depression, CAD, and T2D, a common factor model was specified with all three traits loading onto a latent *multimorbidity* factor.

Multivariate GWAS and heterogeneity index

We used Genomic SEM to carry out a multivariate GWAS whereby the latent factor of multimorbidity (obtained in the previous step) was regressed on each SNP. This permitted a new set of summary statistics to be estimated for this common factor. SNP effects for the latent factor were estimated only for SNPs which were present in each of the univariate summary statistics files, resulting in 6,820,149 SNPs. A follow-up model was specified to obtain a heterogeneity Q index for each SNP. This index indicates the extent to which the SNP effect deviates from the common factor structure, with larger Q_{SNP} values suggesting greater heterogeneity. Heterogeneous SNPs are unlikely to affect all phenotypes via the common factor but, instead, are more likely to be phenotype-specific, and are thus not indicative of multimorbidity. SNPs with Q estimates significant at the genome-wide level ($Q_{\text{SNP}} P < 5e-8$) and with directionally discordant univariate effect estimates were interpreted as potentially heterogeneous. For details, see methods section in [S1 Appendix](#).

Functional annotation and gene mapping

Functional mapping and annotation of genetic associations was performed using FUMA GWAS online platform [51] version 1.5.2d. We used the SNP2GENE pipeline with default settings to identify independent genome-wide significant SNPs ($P < 5e-8$) in low LD ($r^2 < 0.1$). LD blocks of independent significant SNPs that are located next to each other (< 250 kb apart) were merged into one genomic risk locus. To ensure that functional analysis captures the multimorbidity signal and is not driven by any single disease, we removed all SNPs with evidence for heterogeneous effects ($Q_{\text{SNP}} P < 5e-8$ and directionally discordant univariate effect estimates) prior to annotation. Given that independent SNPs might not be causal themselves, but instead in close proximity of causal SNPs, we broadened the genomic loci for annotation to include all known variants that are available in the 1000G reference panel and are in LD ($r^2 \geq 0.6$) with one of the non-heterogeneous, independent significant SNPs, as done elsewhere [51] (methods section in [S1 Appendix](#)).

Subsequently, to understand which genes may be involved in multimorbidity, functionally annotated SNPs were mapped to genes based on positional mapping, expression quantitative trait loci (eQTL) and chromatin interactions ([S1 Appendix](#) methods section). Default

parameters were selected for each of these analyses (S1 Text). LocusZoom platform [52] was used to obtain regional visualization plots of key genomic risk loci.

Pathway enrichment analysis and tissue specificity

All genes identified via at least one of these mapping techniques were used as input in FUMA's GENE2FUNC pipeline, which annotated the prioritised genes in a biological context (S1 Appendix methods section; S2 Text). Enrichment of input genes was tested using curated gene sets and GO terms obtained from MSigDB [53] database and WikiPathways [54], whereas tissue specificity analysis was performed in 54 specific and 30 general tissue types based on GTEx v8 data [55].

Gene-based and gene-set analyses

Given that the effects of individual SNPs can be too weak to detect when dealing with polygenic traits, MAGMA [56] gene-based and gene-set analyses were performed (as implemented within the FUMA platform [51]) to determine the joint effect of multiple SNPs within a given gene. For gene-based analysis, the degree of association for gene with multimorbidity was quantified using gene-based *P*-values, which were obtained by assigning input SNPs to genes when these were physically located within the gene or within 10kb window on either side. For gene-set analysis, gene-set *P*-values were computed for curated gene sets and GO terms obtained from the MSigDB[53] database. Unlike pathway enrichment analysis implemented within the GENE2FUNC pipeline, which only tests for enrichment of prioritized genes, MAGMA gene-set analysis was performed using the full distribution of genetic associations [51]. Significance for gene set analysis was defined as alpha divided by the total number of protein coding genes tested.

Polygenic risk score analysis

To evaluate how well our GWAS for multimorbidity captures multimorbidity risk, we performed polygenic risk score (PRS) analysis. To do this, we first repeated the multivariate GWAS using summary statistics of European ancestry that do not include the UKBB cohort (Table 1). Subsequently, a PRS was calculated using PRSice-2 [57] to assess its association with phenotypic multimorbidity. Summary statistics for multimorbidity (excluding UKBB) provided the allelic weightings for each SNP, which were used to generate polygenic risk scores for 306,734 individuals in the UKBB cohort—our independent target sample—adjusting for 10 genetic principal components (PCs), sex and age. Multimorbidity was defined as an ordinal variable, where 0 = no disease, 1 = any one disease, 2 = any two diseases, and 3 = all three diseases (i.e., depression, CAD and T2D). See methods section in S1 Appendix for further details. Subsequently, a multinomial logistic regression controlling for sex and age was performed to investigate the degree to which the PRS was associated with multimorbidity. To ensure that SNPs with higher heterogeneity estimates do not confer disproportionate liability to any individual trait, we repeated the PRS analysis with non-heterogeneous SNPs only ($Q_{\text{SNP}} P \geq 5e-8$).

To compare how well a multimorbidity-based PRS performs in comparison to PRSs based on single diseases, we generated PRSs for the individual phenotypes as well. Significant differences in the four PRSs (i.e., multimorbidity, CAD, T2D, depression) were tested using one-way ANOVA with post-hoc Tukey HSD to account for multiple comparisons.

Genetic correlations and Mendelian randomization

As a last step, we used the LD score regression tool v1.0.1 [45,58] implemented in Python v2.7.18 to estimate genetic correlations between multimorbidity and 18 risk factors, such as BMI, blood pressure, cholesterol, inflammation, neuroticism, childhood maltreatment and income (see [S1 Appendix](#) methods section for a complete list). For comparability, genetic correlations between the three contributing GWASs (CAD, T2D, depression) and the risk factors were also obtained. Bonferroni correction was applied to account for multiple comparisons.

To further explore which risk factors may be causal for multimorbidity, we performed inverse-variance weighted (IVW) two-sample Mendelian randomization (MR) analysis between selected risk factors and multimorbidity using the TwoSampleMR package [59]. To ensure our outcome GWAS captures multimorbidity, we removed SNPs with evidence of heterogeneity ($Q_{\text{SNP}} P < 5e-8$ and directionally discordant effect estimates). A series of sensitivity analyses were also carried out ([S1 Appendix](#), methods section). All MR analyses were conducted using multimorbidity GWAS without the UKBB. This helped to reduce bias in MR estimates due to sample overlap as eight risk factors were solely based on the UKBB. To account for non-UKBB related sample overlap, we obtained bias-corrected IVW-MR estimates using the recently developed MRlap package[60]. MRlap adjusts for biases due to overlapping samples, weak instruments, and winner's curse by incorporating cross-trait LD-score regression to approximate sample overlap [60].

Results

Heritability and genetic correlations

Heritability estimates (reported on the liability scale) were similar across all three univariate traits: 0.070 ($SE = 0.005$) for CAD, 0.162 ($SE = 0.008$) for T2D, and 0.064 ($SE = 0.002$) for depression. LD score regression identified a significant moderate correlation between CAD and T2D ($r_g = 0.39$, $SE = 0.03$, $P = 2e-34$), and significant but weak correlations between CAD and depression ($r_g = 0.13$, $SE = 0.03$, $P = 3e-6$), and between depression and T2D ($r_g = 0.15$, $SE = 0.02$, $P = 4e-15$). For heritability Z scores, see [S2 Table](#).

Factor analysis

We specified a common factor model where all three traits loaded onto the same multimorbidity factor. T2D loaded most highly on this factor, followed by CAD and depression ([Fig 1](#)). Accordingly, the common factor explained the largest proportion of variance in T2D ($R^2 = 0.45$), followed by CAD ($R^2 = 0.35$) and depression ($R^2 = 0.05$). Hence, the common factor explained on average 28.3% of the total standardised genetic variance between the three traits. Model fit indices were not available due to specifying a fully saturated model ($df = 0$).

Multivariate GWAS and heterogeneity index

We identified 389 SNPs associated with multimorbidity, of which 11 were independent ([Table 2](#), [Figs 2](#) and [B in S1 Appendix](#)). The independent SNPs were distributed across nine genomic loci ([S3 Table](#)). The Q_{SNP} heterogeneity estimate was significant for six of the 11 SNPs ($P < 5e-8$; [S4 Table](#); [Fig C in S1 Appendix](#)).

An inspection of the univariate betas within the three contributing GWASs revealed directionally discordant estimates across the three traits for four of the 11 independent SNPs ([S5 Table](#)), indicating that these particular SNPs were unlikely to operate via the common factor but, instead, were more likely to be phenotype specific. The remaining seven SNPs were consistent in the direction of their univariate betas, with four SNPs showing the largest effects




Fig 1. A Common Factor Model for Psycho-Cardiometabolic Multimorbidity. Unstandardized coefficients (SE) on the left and standardized coefficients (SE) on the right for the genetically defined common factor of multimorbidity. The model uses unit variance identification for the latent factor. All paths are significant at $P < 2e-13$. MM, multimorbidity; CAD, coronary artery disease; T2D, type 2 diabetes; MD, major depression; U, residual variance.

<https://doi.org/10.1371/journal.pgen.1010508.g001>

for CAD and T2D, and three SNPs having comparable estimates across the three traits (for regional plots of these SNPs see Fig 2). While we observed moderate genomic inflation (i.e., λ_{GC} of 1.69), an intercept of 0.99 ($SE = 0.01$) indicated that it was likely due to polygenicity rather than uncontrolled inflation (S2 Table). The effective sample size for the multimorbidity GWAS was 562,507.

Table 2. Independent Significant SNPs at $r^2 < 0.1$ identified in the Multivariate GWAS of Psycho-Cardiometabolic Multimorbidity.

Locus	rsID	Chr	Position	P-value	LD SNPs	GWAS SNPs	Q_{SNP} P-value	Nearest Gene
1	rs10789340	1	72940273	3.38E-10	580	394	3.15e-12	<i>RPL31P12</i>
2	rs9349379*	6	12903957	3.17E-19	222	135	2.91e-27	<i>PHACTR1</i>
3	rs10455872*	6	161010118	4.81E-15	200	143	1.55e-25	<i>LPA</i>
3	rs186696265*	6	161111700	3.78E-11	91	56	7.53e-21	<i>RP1-81D8.3</i>
4	rs2043539	7	12253880	1.23E-08	329	210	3.52e-07	<i>TMEM106B</i>
5	rs3731239	9	21974218	3.03E-09	167	113	3.45e-06	<i>RP11-145E5.5: CDKN2A</i>
5	rs2891168	9	22098619	6.88E-74	215	155	1.36e-27	<i>CDKN2B-AS1</i>
6	rs532436	9	136149830	2.88E-08	168	65	8.93e-06	<i>ABO</i>
7	rs34872471*	10	114754071	2.32E-11	133	109	1.85e-17	<i>TCF7L2</i>
8	rs2004910	12	121374727	3.60E-09	493	337	0.003	<i>RPL12P33</i>
9	rs1962412	17	46970259	2.57E-08	510	359	0.095	<i>SUMO2P17: ATP5G1</i>

rsID, unique identifier of independent significant single nucleotide polymorphisms (SNPs); Chr, chromosome; Position, position on hg19. LD SNPs = the number of SNPs in linkage disequilibrium (LD) with the corresponding independent significant SNP. This includes non-GWAS-tagged SNPs extracted from 1000G reference panel. GWAS SNPs = number of multimorbidity GWAS-tagged SNPs in LD ($r^2 < 0.1$) with the corresponding independent significant SNP filtered by $P \leq 0.05$. Q_{SNP} P-value = test for violation of the null hypothesis that the SNP acts entirely through the common factor. An asterisk indicates heterogeneous SNPs with a $Q_{SNP} P < 5e-8$ and directionally discordant univariate betas. While another two SNPs had $Q_{SNP} P < 5e-8$ indicative of heterogeneity, their univariate beta estimates were directionally concordant.

<https://doi.org/10.1371/journal.pgen.1010508.t002>




Fig 2. Manhattan and LocusZoom Plots of the Multivariate GWAS of Psycho-Cardiometabolic Multimorbidity. (A) A Manhattan plot displaying the results for the multivariate GWAS of psycho-cardiometabolic multimorbidity obtained using Genomic SEM (with Diagonally Weighted Least Squares estimation). The y axis depicts $-\log_{10}(P)$ values for variants associated with multimorbidity. The dashed, horizontal grey line denotes the genome-wide significance threshold at $P = 5e-8$. Points above the grey line represent genome-wide significant hits. The black diamonds represent independent hits. The grey stars represent independent SNPs with evidence for heterogeneous effects ($Q_{SNP} P < 5e-8$ and directionally discordant univariate effect estimates). (B, C, D) Regional plots centered on three top variants (rs10789340, rs2043539 and rs2004910, respectively) that have comparable univariate estimates across coronary artery disease, type 2 diabetes and depression. Coding genes are shown in the panel below. The blue line represents the recombination rate.

<https://doi.org/10.1371/journal.pgen.1010508.g002>

Functional annotation and gene mapping

To ensure that functional analysis captured multimorbidity and was not driven by any single disease, we only included non-heterogeneous SNPs and those in LD. This left 1,562 GWAS tagged SNPs, which were functionally annotated to genes based on positional mapping, eQTL associations and chromatin interactions using FUMA. A total of 200 unique genes were implicated by at least one of these mapping techniques while 37 were identified using all three methods. For a complete list of prioritised genes refer to [S6 Table](#).

Gene-based analysis of all SNPs

Gene-based analysis using MAGMA[56] provided P -values for the joint association effect of *all* non-heterogeneous SNPs. Non-heterogeneous SNPs were mapped to 18,931 protein coding genes, with 122 of these genes being identified as significant after correcting for the number of genes tested ($P = 0.05/18931 = 2.64e-6$). Eighteen genes identified using MAGMA overlapped with the genes implicated by FUMA, providing stronger support for the involvement of these particular genes ([Table 3](#)).

Pathway enrichment analysis and tissue specificity of prioritised genes

The prioritised genes demonstrated enrichment in 10 Reactome pathways, three GO molecular functions, 43 GO biological processes, nine KEGG and 25 canonical pathways, among others. Based on an FDR-adjusted P -value, the strongest enrichment was observed in immune system and cytokine related pathways such as “regulation of IFN α signalling”, “interferon receptor binding”, “cytokine activity”, “serine phosphorylation of STAT protein”, and “natural

Table 3. MAGMA results for 18 genes identified using four distinct methods: MAGMA gene-based analysis, positional, eQTL and chromatin interaction mapping.

Gene	Status	Chr	Start	End	nSNPs	Z	P-value ^a
<i>NEGR1</i>	confirmed	1	71851623	72758417	1673	5.37	3.87E-08
<i>TMEM106B</i>	confirmed	7	12240867	12292993	272	5.40	3.30E-08
<i>RP11-145E5.5</i>	novel	9	21792635	22042985	412	6.91	2.40E-12
<i>C9orf53</i>	novel	9	21957137	21977738	19	6.07	6.34E-10
<i>CDKN2A</i>	novel	9	21957751	22005300	48	7.08	7.40E-13
<i>CDKN2B</i>	novel	9	21992902	22019362	37	7.85	2.05E-15
<i>SPPL3</i>	novel	12	121190313	121352174	463	5.78	3.70E-09
<i>AC079602.1</i>	novel	12	121397641	121420095	66	6.27	1.85E-10
<i>HNF1A</i>	confirmed	12	121406346	121450315	143	5.87	2.18E-09
<i>C12orf43</i>	novel	12	121430225	121464305	110	5.74	4.63E-09
<i>OASL</i>	novel	12	121448095	121487045	118	5.75	4.42E-09
<i>TTL6</i>	novel	17	46829597	46904576	205	5.33	4.99E-08
<i>ATP5G1</i>	novel	17	46960127	46983233	48	5.66	7.58E-09
<i>UBE2Z</i>	novel	17	46975731	47016418	112	5.43	2.82E-08
<i>SNF8</i>	novel	17	46996678	47032479	110	5.47	2.19E-08
<i>GIP</i>	novel	17	47025916	47055958	92	5.62	9.51E-09
<i>IGF2BP1</i>	novel	17	47064774	47143012	125	5.30	5.78E-08
<i>TCF4</i>	novel	18	52879562	53342018	668	4.75	1.03E-06

Confirmed status refers to genes that have been associated with all three disorders (i.e., coronary artery disease, type 2 diabetes and depression) in previous studies.

Novel status refers to genes that are for the first time being linked to all three disorders. Chr, chromosome; nSNPs, number of single nucleotide polymorphisms; Z, Z-statistic; eQTL, expression quantitative trait loci.

^aBonferroni corrected *P*-value threshold was set at 0.05 / (the number of tested genes) = 2.64e-6.

<https://doi.org/10.1371/journal.pgen.1010508.t003>

killer cell activation involved in immune response". For complete results of gene set enrichment analysis see [S7 Table](#). Tissue specificity analysis using 53 specific and 30 general GTEx tissue types demonstrated significant enrichment of upregulated differentially expressed gene sets in kidney ($P_{\text{Bon}} < 0.001$; Fig D in [S1 Appendix](#)) and kidney cortex tissues ($P_{\text{Bon}} = 0.003$; Fig E in [S1 Appendix](#)).

MAGMA gene-set and tissue expression analyses

Out of all 15,485 gene sets tested (in comparison to only prioritised genes above), MAGMA gene set analysis identified five significant gene sets related to processes such as DNA binding, nucleic acid binding, and regulation of respiratory system process (all $P_{\text{Bon}} < 0.031$; [S8 Table](#)). Lastly, tissue specificity analysis revealed significant gene expression in the cerebellum ($P_{\text{Bon}} = 0.040$; Fig F in [S1 Appendix](#)) and the pituitary gland ($P_{\text{Bon}} = 0.045$; Fig G in [S1 Appendix](#)), relative to other tissue types.

Polygenic risk score analysis

To validate the latent multimorbidity factor, we derived a PRS for multimorbidity in the UKBB cohort ($N = 306,734$). To do this, we first repeated the multivariate GWAS using summary-level data that did not include the UKBB. Results aligned very closely to our discovery GWAS (see [results](#) section in [S1 Appendix](#), [S4](#) and [S9 Tables](#) for more detail). In UKBB, we observed a dose-response relationship, whereby PRS for multimorbidity was lowest in healthy individuals ($M = -0.037$, $SE = 0.002$), followed by individuals with any one disease ($M = 0.111$, $SE = 0.004$) and any two diseases ($M = 0.379$, $SE = 0.013$). PRS was highest in individuals with




Fig 3. Out-of-Sample Prediction for Phenotypic Psycho-Cardiometabolic Multimorbidity or Single Diseases using Polygenic Risk Scores. (A) Multimorbidity polygenic risk score across groups of individuals with no, any one, two or three diseases. (B) Four polygenic risk scores for MD, CAD, T2D, and multimorbidity across groups of individuals with no, any one, two or three diseases. MD, major depression; CAD, coronary artery disease; T2D, type 2 diabetes; MM, multimorbidity; PRS, polygenic risk score.

<https://doi.org/10.1371/journal.pgen.1010508.g003>

all three diseases ($M = 0.585$, $SE = 0.046$), which aligned well with the common factor structure specified using Genomic SEM (Fig 3; S10 Table) and suggested that findings were not driven solely by the comorbidity between CAD and T2D. Results from multinomial logistic regression revealed that for one standard deviation increase in multimorbidity-PRS, the odds of experiencing multimorbidity (i.e., co-occurrence of CAD, T2D and depression) increased by 91% relative to the healthy group ($OR = 1.91$, 95% CI = 1.74–2.10). Multimorbidity-PRS was best suited at predicting multimorbidity, rather than any one (OR range = 1.07–1.38) or any two diseases (OR range = 1.46–1.73). Additionally, multimorbidity-PRS outperformed individual PRSs based on CAD, T2D, and depression, especially for the multimorbid group (Table 4). A PRS analysis using only non-heterogeneous SNPs ($Q_{SNP} P \geq 5e-8$) returned almost identical results (S10 Table).

Furthermore, the four PRSs were statistically different in individuals with multimorbidity, $F(3, 1740) = 7.32$, $P < .001$. Tukey's HSD test indicated that the multimorbidity PRS

Table 4. Association between four Polygenic Risk Scores and Disease Status in UK Biobank adjusted for Age and Sex using Multinomial Logistic Regression ($N = 306,734$).

Outcome	MM-PRS Adjusted OR (95% CI)	CAD-PRS Adjusted OR (95% CI)	T2D-PRS Adjusted OR (95% CI)	MD-PRS Adjusted OR (95% CI)
Healthy	Ref	Ref	Ref	Ref
MD only	1.07 (1.06–1.08)	1.01 (1.00–1.02)	1.01 (0.99–1.02)	1.20 (1.18–1.21)
T2D only	1.36 (1.33–1.38)	1.13 (1.11–1.15)	1.42 (1.40–1.45)	1.07 (1.05–1.10)
CAD only	1.38 (1.35–1.41)	1.41 (1.38–1.44)	1.07 (1.05–1.09)	1.1 (1.07–1.12)
MD and T2D	1.46 (1.40–1.52)	1.16 (1.12–1.21)	1.44 (1.38–1.5)	1.24 (1.19–1.30)
MD and CAD	1.46 (1.39–1.53)	1.37 (1.31–1.44)	1.09 (1.04–1.14)	1.27 (1.21–1.33)
CAD and T2D	1.73 (1.66–1.81)	1.44 (1.38–1.50)	1.52 (1.46–1.59)	1.19 (1.14–1.24)
Multimorbidity	1.91 (1.74–2.10)	1.53 (1.39–1.68)	1.53 (1.39–1.68)	1.38 (1.25–1.51)

Polygenic risk scores have been standardised. Reference category = healthy. Multimorbidity = CAD + T2D + MD. OR, odds ratio; CI, confidence interval; MM, multimorbidity; CAD, coronary artery disease; T2D, type 2 diabetes; MD, major depression.

<https://doi.org/10.1371/journal.pgen.1010508.t004>

($M = 0.59$, $SE = 0.05$) was significantly higher in individuals with all three diseases than PRSs for depression ($M = 0.29$, $SE = 0.05$, $P_{adj} = .001$), CAD ($M = 0.38$, $SE = 0.05$, $P_{adj} = .011$), or T2D ($M = 0.39$, $SE = 0.05$, $P_{adj} = .015$; Fig 3).

A sex-stratified analysis using multinomial logistic regression revealed comparable results for males and females. Specifically, relative to the healthy group, for every one standard deviation increase in multimorbidity-PRS, the odds of experiencing multimorbidity increased by 94% (OR = 1.94, 95% CI = 1.73–2.17) for males and 86% (OR = 1.86, 95% CI = 1.57–2.20) for females (S10 and S11 Table).

Genetic correlations and Mendelian randomization

Results from LD score regression revealed significant genetic correlations with multimorbidity for 17 out of 18 risk factors (all $P_{Bon} < 0.002$). The strongest genetic correlations were observed for BMI ($r_g = 0.60$, $SE = 0.02$, $P_{Bon} = 9e-251$), body fat percentage ($r_g = 0.56$, $SE = 0.02$, $P_{Bon} = 3e-174$), and C-reactive protein (CRP; $r_g = 0.41$, $SE = 0.04$, $P_{Bon} = 3e-20$). Interestingly, moderate correlations were also observed with insomnia ($r_g = 0.36$, $SE = 0.03$, $P_{Bon} = 2e-44$), neuroticism ($r_g = 0.33$, $SE = 0.02$, $P_{Bon} = 2e-55$), and childhood maltreatment ($r_g = 0.33$, $SE = 0.03$, $P_{Bon} = 1e-32$) (S12 Table).

Mendelian randomization analyses revealed potentially causal associations of BMI, body fat percentage, LDL cholesterol, total cholesterol, fasting insulin, income, insomnia, and childhood maltreatment that survived correction for multiple testing using the Benjamini-Hochberg (BH) false discovery rate. Sensitivity analyses estimates using MR-Egger, simple mode, weighted median and weighted mode methods were generally consistent for all these traits (with a minimum of three out of four sensitivity analyses having significant causal estimates), indicating robustness of our primary results (Fig 4; S13 Table). Evidence for neuroticism, blood pressure traits, and triglycerides was more mixed. We found little or no evidence to support a causal effect of intelligence, worry, sensitivity to environmental stress and adversity, HDL cholesterol, smoking status, and C-reactive protein (Figs H–Y in S1 Appendix; S13 Table). Results from the remaining sensitivity analyses and MRlap are reported in the supplementary material (S1 Appendix, results section and Figs H–Y; S13–S14 Tables).

Discussion

The present study explored the multivariate genetic architecture of major depression, T2D, and CAD. Assessment of bivariate genetic correlations suggested a shared genetic architecture between all three disorders. The strongest correlation was observed between CAD and T2D ($r_g = 0.39$), with weaker correlations detected between depression and CAD ($r_g = 0.13$) and depression and T2D ($r_g = 0.15$), suggesting a more distinct genetic basis. This was in line with findings from previous studies which reported genetic correlations of a similar magnitude [44–46].

Akin to the bivariate correlation pattern we observed, results from the factor analysis also revealed that on the genetic level, psycho-cardiometabolic multimorbidity is most representative of CAD and T2D, but less so of depression. Using this factor structure, we identified 11 independent SNPs associated with multimorbidity across nine genomic loci. The direction of effect estimates was concordant across CAD, T2D and depression for seven of the 11 variants, suggesting consistent risk associations with multimorbidity. For the majority of SNPs ($n = 7$), the largest effects were observed for CAD and T2D. Three SNPs (rs10789340, rs2043539, rs2004910) had comparable effect estimates across the three traits.

Six of the 11 independent SNPs were previously identified as genome-wide significant in the contributing GWAS of CAD [48]. Four of the 11 independent SNPs were also identified as genome-wide significant in the contributing GWAS of T2D [42], and three were identified as




Fig 4. Scatter plots of Two-Sample Mendelian Randomization results. Scatter plots showing SNP effects of body mass index (A), body fat percentage (B), LDL cholesterol (C), total cholesterol (D), fasting insulin (E), income (F), insomnia (G), and childhood maltreatment (H) on psycho-cardiometabolic multimorbidity. The slopes represent estimates from the primary (inverse variance weighted) and sensitivity analyses (MR-Egger, simple mode, weighted median, weighted mode). MR, Mendelian randomization; LDL, low-density lipoprotein; SNP, single nucleotide polymorphism.

<https://doi.org/10.1371/journal.pgen.1010508.g004>

genome-wide significant in the GWAS of depression [44]. While this was indicative of greater shared genetic architecture underlying CAD and T2D, it could also partially be driven by the smaller effect sizes generally observed for depression-associated SNPs [44]. Weaker associations with depression may also be attributable to greater polygenicity and heterogeneity of depression. Individuals with the same diagnoses of depression may express very different—and even opposing (e.g., increase or decrease in sleep and appetite)—symptom profiles that, in turn, may be related to different pathophysiological mechanisms. For example, previous research has shown that PRSs for higher body mass index, triglycerides [61], C-reactive protein and leptin [62,63] were specifically associated with major depression characterized by atypical symptoms (such as hyperphagia, hypersomnia and weight gain) but not with major depression in general or with other specific subtypes. Thus, lumping different symptom patterns may weaken or dilute genetic associations [64].

Focusing on non-heterogeneous SNPs to minimize genetic signals driven by a single disorder, FUMA prioritised 200 genes putatively associated with multimorbidity, 18 of which were also identified using positional mapping, eQTL mapping, chromatin interaction mapping, and MAGMA gene-based analysis, thereby providing the most consistent support for these genes. Three of these genes (*NEGR1*, *TMEM106B*, *HNF1A*) have been linked to each of the three diseases (CAD, T2D and depression) in previous studies [44,65–74], supporting their probable involvement in psycho-cardiometabolic multimorbidity. The remaining 15 were completely novel (e.g., *SNF8* and *AC079602.1*) or had only been linked to one or two diseases. For example, while *SPPL3* and *TCF4* have been associated with T2D [42,67] and depression [72,75,76] (as well as various other psychiatric traits [77,78]), an association with CAD has not yet been reported. However, *SPPL3* and *TCF4* have been linked to CAD risk factors such as cholesterol levels [79,80] and CRP [79,81,82], suggesting a potential role in multimorbidity. Similarly, *UBE2Z*, *GIP* and *IGF2BP1* have been linked to CAD [70,83,84], T2D [66,67,85], and depression-related traits such as insomnia, BMI, educational attainment, CRP levels, platelet count and smoking [82,86–92]. As such, even though a direct association with depression has not yet been established, their relevance in psycho-cardiometabolic multimorbidity seems biologically plausible.

A similar pattern was observed for the other genes, whereby the majority tagged common risk factors for CAD, T2D and depression, such as adiposity related traits (BMI, body fat percentage, waist/hip circumference), inflammatory markers (CRP, interleukin-6, interleukin-5), lipids (low- and high-density lipoprotein levels), platelet traits (platelet count, plateletcrit), and N-glycan levels [42,70,79,87,93–100]. Previous knowledge for three of the identified genes (*RP11-145E5.5*, *SNF8*, *AC079602.1*) was weak, suggesting potentially novel targets for follow-up in relation to multimorbidity.

The prioritised genes showed an enrichment in immune and cytokine related pathways, which are involved in the regulation of immune and inflammatory responses—both of which have been implicated in the pathophysiology of CAD, T2D and depression. For example, interferons and cytokines play a central role in the innate immune system and in the initiation of inflammatory cascades [101,102]. Experimental and longitudinal studies suggest that for a significant subset of patients, immune system dysfunction in general and inflammation in particular may be causally implicated in the development of depression [103–106]. A recent study showed that higher interleukin 6 activity is potentially causal especially for specific symptoms of depression, such as sleep problems or fatigue [107]. Similarly, chronic inflammation has been identified as a feature of CAD, promoting the growth of plaques in the arteries and worsening clinical outcomes, irrespective of serum lipid levels [108,109]. Innate and adaptive immunity, together with low-grade inflammation have also been recognised as important aetiological factors in the pathogenesis of insulin resistance and T2D [110]. Hence, the

implicated genes and biological processes reflect biological plausibility for shared genetic aetiology between CAD, T2D and depression. On the other hand, it is also possible that an inflammatory response is the downstream effect of these diseases.

Tissue specificity analysis indicated increased gene expression relative to other tissue types in the cerebellum and the pituitary gland. This is of interest as the structure and function of these regions seems to be altered in depression. For example, individuals with depression tend to have an overactive hypothalamic-pituitary-adrenal axis (our main stress response system), leading to increased cortisol levels and suppressed immune responses [20]. Similarly, with regard to the cerebellum, important cerebellar alterations have been identified in patients with depression [111], impacting emotion regulation ability [112]. Despite the limited contribution of depression to the latent multimorbidity factor, the involvement of these two regions provides reassurance that depression is captured in our analysis. This is further supported by genetic correlation and MR results between a number of depression-related risk factors, such as insomnia, childhood maltreatment and adiposity traits.

Overall, while we observed weak-to-strong genetic correlations between 17 risk factors and multimorbidity, only eight of these associations (BMI, body fat percentage, LDL cholesterol, total cholesterol, fasting insulin, income, insomnia, and childhood maltreatment) demonstrated consistent estimates across most MR analyses, suggesting potentially causal effects.

The findings of the present study should be interpreted in light of the following limitations. First, we only considered common genetic variants, but it is also possible that multimorbidity is driven by rare variants with minor allele frequencies below 1%. Second, the contributing GWAS by Nikpay et al. [48] included mixed ancestry individuals (23%), which is cautioned against when using Genomic SEM. However, as the LD score intercepts for CAD and multimorbidity GWASs were close to 1 (0.88 and 0.99, respectively), suggests that our results are unlikely to be biased due to ancestry issues. Third, although we removed SNPs with strong evidence for heterogeneity ($Q_{\text{SNP}} P < 5e-8$ and directionally discordant univariate effect estimates), there were still many variants left in the analyses with suggestive evidence for heterogeneity. This means that our downstream analyses may be biased towards pathways related to any one or two constituting diseases. Therefore, when using multimorbidity summary statistics in future studies, it may be appropriate to apply an even more stringent heterogeneity threshold (e.g., $P < 5e-6$), depending on the nature of the investigation.

Fourth, multimorbidity was defined by the common factor structure we specified using Genomic SEM, where the latent variable accounted for the largest proportion of variance in T2D and CAD, with a smaller amount of variance explained in depression. This had implications for the identification of genetic variants and the prioritisation of genes, which were based on the latent multimorbidity factor and were therefore capturing depression to a lesser extent. Genetic variants identified based on such a factor structure may put into question the interpretability of current results, as SNPs for multimorbidity may simply reflect the prespecified factor structure (i.e., an effect of the GWASs used) rather than a robust finding. However, considering that (1) the mean PRS was larger in individuals with all three diseases compared to those with any one or two diseases and (2) a multimorbidity PRS (as opposed to PRSs for single diseases) was most strongly associated with multimorbidity phenotype, suggests that the present study detected putative pleiotropic variants that influence CAD, T2D and depression.

In summary, the present study investigated the shared genetic architecture across CAD, T2D and depression and performed a multivariate GWAS of psycho-cardiometabolic multimorbidity. The analysis identified 11 independent SNPs associated with multimorbidity and 18 putative multimorbidity-associated genes. Three of these genes had already been linked to each of the three diseases in previous studies and 15 were novel or had only been linked to one or two diseases. The prioritised genes were enriched in immune and inflammatory pathways,

elucidating putative biological mechanisms underlying psycho-cardiometabolic multimorbidity. Considering that susceptibility to CAD, T2D and depression is also influenced by environmental factors [113–116], future studies should explore multimorbidity in the context of gene-environment correlations and interactions. Lastly, to decipher the role of depression heterogeneity, similar analyses could be performed using subgroups of individuals characterized by different depression profiles (e.g., atypical symptoms, inflammation).

Overall, our findings advance our understanding of genetic associations related to multimorbidity and provide avenues for future research.

Web resources

Genomic SEM: <https://github.com/GenomicSEM/GenomicSEM/wiki>.

LDSC package in Python: <https://github.com/bulik/ldsc>.

FUMA GWAS online platform: <https://fuma.ctglab.nl>.

PRSice-2: https://choishingwan.github.io/PRSice/step_by_step/.

LocusZoom: <http://locuszoom.org/>.

Supporting information

S1 Table. Population characteristics of the input genome-wide association meta-analyses.
(XLSX)

S2 Table. LD score regression results for univariate (input) and multivariate genome-wide association studies.
(XLSX)

S3 Table. Genomic risk loci from the multivariate GWAS of psycho-cardiometabolic multimorbidity.
(XLSX)

S4 Table. Genomic SEM output for independent significant SNPs from the multivariate GWAS of psycho-cardiometabolic multimorbidity.
(XLSX)

S5 Table. Univariate coefficients and their standard errors scaled relative to unit-variance scaled phenotypes.
(XLSX)

S6 Table. A list of prioritized genes by functional mapping in the discovery GWAS of psycho-cardiometabolic multimorbidity.
(XLSX)

S7 Table. Results of gene set enrichment analysis.
(XLSX)

S8 Table. MAGMA gene-set analysis containing one P-value per gene set.
(XLSX)

S9 Table. A list of prioritized genes by functional mapping in the multivariate GWAS of psycho-cardiometabolic multimorbidity (version without UK Biobank).
(XLSX)

S10 Table. Proportion of multimorbid individuals in UK Biobank and their polygenic risk scores calculated using PRSice-2.
(XLSX)

S11 Table. Sex-stratified results for the association between multimorbidity polygenic risk score and disease status in UK Biobank.

(XLSX)

S12 Table. Results of LD Score regression analyses between psycho-cardiometabolic multimorbidity and various risk factors.

(XLSX)

S13 Table. Results from two-sample Mendelian randomization using inverse variance weighted method as the primary analysis and MR-Egger, simple mode, weighted median and weighted mode methods as sensitivity analyses.

(XLSX)

S14 Table. Results for Mendelian randomization Steiger test of directionality.

(XLSX)

S1 Appendix. Supplementary Appendix.

(PDF)

S1 Text. FUMA SNP2GENE parameters.

(DOCX)

S2 Text. FUMA GENE2FUNC parameters.

(DOCX)

Acknowledgments

We are grateful to the UK Biobank and all its voluntary participants. We also thank all 23andMe research participants who made this study possible.

Author Contributions

Conceptualization: Vilte Baltramonaityte, Jean-Baptiste Pingault, Charlotte A. M. Cecil, Janine Felix, Sylvain Sebert, Yuri Milaneschi, Esther Walton.

Formal analysis: Vilte Baltramonaityte.

Methodology: Vilte Baltramonaityte, Jean-Baptiste Pingault, Yuri Milaneschi, Esther Walton.

Supervision: Sylvain Sebert, Esther Walton.

Writing – original draft: Vilte Baltramonaityte.

Writing – review & editing: Vilte Baltramonaityte, Jean-Baptiste Pingault, Charlotte A. M. Cecil, Priyanka Choudhary, Marjo-Riitta Järvelin, Brenda W. J. H. Penninx, Janine Felix, Sylvain Sebert, Yuri Milaneschi, Esther Walton.

References

1. Murray CJL, Barber RM, Foreman KJ, Ozgoren AA, Abd-Allah F, Abera SF, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. *The Lancet*. 2015; 386: 2145–2191. [https://doi.org/10.1016/S0140-6736\(15\)61340-X](https://doi.org/10.1016/S0140-6736(15)61340-X) PMID: 26321261
2. Amare AT, Schubert KO, Klingler-Hoffmann M, Cohen-Woods S, Baune BT. The genetic overlap between mood disorders and cardiometabolic diseases: a systematic review of genome wide and candidate gene studies. *Transl Psychiatry*. 2017; 7: e1007–e1007. <https://doi.org/10.1038/tp.2016.261> PMID: 28117839

3. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *The Lancet*. 2012; 380: 37–43. [https://doi.org/10.1016/S0140-6736\(12\)60240-2](https://doi.org/10.1016/S0140-6736(12)60240-2) PMID: 22579043
4. Nicholson A, Kuper H, Hemingway H. Depression as an aetiological and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. *Eur Heart J*. 2006; 27: 2763–2774. <https://doi.org/10.1093/eurheartj/ehl338> PMID: 17082208
5. Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and Type 2 Diabetes Over the Lifespan: A meta-analysis. *Diabetes Care*. 2008; 31: 2383–2390. <https://doi.org/10.2337/dc08-0985> PMID: 19033418
6. Yu M, Zhang X, Lu F, Fang L. Depression and Risk for Diabetes: A Meta-Analysis. *Can J Diabetes*. 2015; 39: 266–272. <https://doi.org/10.1016/j.cjcd.2014.11.006> PMID: 25773933
7. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The Prevalence of Comorbid Depression in Adults With Diabetes: A meta-analysis. *Diabetes Care*. 2001; 24: 1069–1078. <https://doi.org/10.2337/diacare.24.6.1069> PMID: 11375373
8. Dickens C. Depression in People with Coronary Heart Disease: Prognostic Significance and Mechanisms. *Curr Cardiol Rep*. 2015; 17: 83. <https://doi.org/10.1007/s11886-015-0640-6> PMID: 26277367
9. Laursen TM, Musliner KL, Benros ME, Vestergaard M, Munk-Olsen T. Mortality and life expectancy in persons with severe unipolar depression. *J Affect Disord*. 2016; 193: 203–207. <https://doi.org/10.1016/j.jad.2015.12.067> PMID: 26773921
10. Guerrero Fernández de Alba I, Gimeno-Miguel A, Poblador-Plou B, Gimeno-Feliu LA, Ioakeim-Skoufa I, Rojo-Martínez G, et al. Association between mental health comorbidity and health outcomes in type 2 diabetes mellitus patients. *Sci Rep*. 2020; 10: 19583. <https://doi.org/10.1038/s41598-020-76546-9> PMID: 33177607
11. May HT, Horne BD, Knight S, Knowlton KU, Bair TL, Lappé DL, et al. The association of depression at any time to the risk of death following coronary artery disease diagnosis. *Eur Heart J—Qual Care Clin Outcomes*. 2017; 3: 296–302. <https://doi.org/10.1093/ehjqcco/qcx017> PMID: 28950317
12. Bassuk SS, Manson JE. Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease. *J Appl Physiol*. 2005; 99: 1193–1204. <https://doi.org/10.1152/jappphysiol.00160.2005> PMID: 16103522
13. Pedersen BK, Saltin B. Exercise as medicine—evidence for prescribing exercise as therapy in 26 different chronic diseases. *Scand J Med Sci Sports*. 2015; 25: 1–72. <https://doi.org/10.1111/sms.12581> PMID: 26606383
14. Sánchez-Villegas A, Toledo E, de Irala J, Ruiz-Canela M, Pla-Vidal J, Martínez-González MA. Fast-food and commercial baked goods consumption and the risk of depression. *Public Health Nutr*. 2012; 15: 424–432. <https://doi.org/10.1017/S1368980011001856> PMID: 21835082
15. Cahill LE, Pan A, Chiuve SE, Sun Q, Willett WC, Hu FB, et al. Fried-food consumption and risk of type 2 diabetes and coronary artery disease: a prospective study in 2 cohorts of US women and men. *Am J Clin Nutr*. 2014; 100: 667–675. <https://doi.org/10.3945/ajcn.114.084129> PMID: 24944061
16. Roberts RE, Deleger S, Strawbridge WJ, Kaplan GA. Prospective association between obesity and depression: evidence from the Alameda County Study. *Int J Obes*. 2003; 27: 514–521. <https://doi.org/10.1038/sj.jco.0802204> PMID: 12664085
17. Geng T, Smith CE, Li C, Huang T. Childhood BMI and Adult Type 2 Diabetes, Coronary Artery Diseases, Chronic Kidney Disease, and Cardiometabolic Traits: A Mendelian Randomization Analysis. *Diabetes Care*. 2018; 41: 1089–1096. <https://doi.org/10.2337/dc17-2141> PMID: 29483184
18. Wade KH, Chiesa ST, Hughes AD, Chaturvedi N, Charakida M, Rapala A, et al. Assessing the Causal Role of Body Mass Index on Cardiovascular Health in Young Adults: Mendelian Randomization and Recall-by-Genotype Analyses. *Circulation*. 2018; 138: 2187–2201. <https://doi.org/10.1161/CIRCULATIONAHA.117.033278> PMID: 30524135
19. Rosmond R, Bjorntorp P. The hypothalamic-pituitary-adrenal axis activity as a predictor of cardiovascular disease, type 2 diabetes and stroke. *J Intern Med*. 2000; 247: 188–197. <https://doi.org/10.1046/j.1365-2796.2000.00603.x> PMID: 10692081
20. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. *Trends Neurosci*. 2008; 31: 464–468. <https://doi.org/10.1016/j.tins.2008.06.006> PMID: 18675469
21. Pasco JA, Nicholson GC, Williams LJ, Jacka FN, Henry MJ, Kotowicz MA, et al. Association of high-sensitivity C-reactive protein with de novo major depression. *Br J Psychiatry*. 2010; 197: 372–377. <https://doi.org/10.1192/bjp.bp.109.076430> PMID: 21037214
22. Pradhan AD. C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus. *JAMA*. 2001; 286: 327. <https://doi.org/10.1001/jama.286.3.327> PMID: 11466099

23. Hashmi S, Zeng QT. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. *Coron Artery Dis*. 2006; 17: 699–706. <https://doi.org/10.1097/01.mca.0000236288.94553.b4> PMID: 17119379
24. Souama C, Lamers F, Milaneschi Y, Vinkers CH, Defina S, Garvert L, et al. Depression, cardiometabolic disease, and their co-occurrence after childhood maltreatment: an individual participant data meta-analysis including over 200,000 participants. *BMC Med*. 2023; 21: 93. <https://doi.org/10.1186/s12916-023-02769-y> PMID: 36907864
25. van den Broek N, Treur JL, Larsen JK, Verhagen M, Verweij KJH, Vink JM. Causal associations between body mass index and mental health: a Mendelian randomisation study. *J Epidemiol Community Health*. 2018; 72: 708–710. <https://doi.org/10.1136/jech-2017-210000> PMID: 29666151
26. Fall T, Hägg S, Mägi R, Ploner A, Fischer K, Horikoshi M, et al. The Role of Adiposity in Cardiometabolic Traits: A Mendelian Randomization Analysis. Minelli C, editor. *PLoS Med*. 2013; 10: e1001474. <https://doi.org/10.1371/journal.pmed.1001474> PMID: 23824655
27. Larsson SC, Bäck M, Rees JMB, Mason AM, Burgess S. Body mass index and body composition in relation to 14 cardiovascular conditions in UK Biobank: a Mendelian randomization study. *Eur Heart J*. 2020; 41: 221–226. <https://doi.org/10.1093/eurheartj/ehz388> PMID: 31195408
28. Dardani C, Yarmolinsky J, Robinson J, Zheng J, Smith GD, Lewis SJ, et al. Disentangling causal relationships between inflammatory markers and depression: a bidirectional Mendelian randomization analysis. *Genomics*. 2019 Jul. <https://doi.org/10.1101/712133>
29. Georgakis MK, Malik R, Gill D, Franceschini N, Sudlow CLM, Dichgans M, et al. Interleukin-6 Signaling Effects on Ischemic Stroke and Other Cardiovascular Outcomes: A Mendelian Randomization Study. *Circ Genomic Precis Med*. 2020; 13: e002872. <https://doi.org/10.1161/CIRCGEN.119.002872> PMID: 32397738
30. Cheng L, Zhuang H, Yang S, Jiang H, Wang S, Zhang J. Exposing the Causal Effect of C-Reactive Protein on the Risk of Type 2 Diabetes Mellitus: A Mendelian Randomization Study. *Front Genet*. 2018; 9: 657. <https://doi.org/10.3389/fgene.2018.00657> PMID: 30619477
31. Wium-Andersen MK, Ørsted DD, Nordestgaard BG. Elevated C-Reactive Protein, Depression, Somatic Diseases, and All-Cause Mortality: A Mendelian Randomization Study. *Biol Psychiatry*. 2014; 76: 249–257. <https://doi.org/10.1016/j.biopsych.2013.10.009> PMID: 24246360
32. Galan D, Perry BI, Warrier V, Davidson CC, Stupart O, Easton D, et al. Applying Mendelian randomization to appraise causality in relationships between smoking, depression and inflammation. *Sci Rep*. 2022; 12: 15041. <https://doi.org/10.1038/s41598-022-19214-4> PMID: 36057695
33. Brunner EJ, Kivimäki M, Witte DR, Lawlor DA, Smith GD, Cooper JA, et al. Inflammation, Insulin Resistance, and Diabetes—Mendelian Randomization Using CRP Haplotypes Points Upstream. Keavney B, editor. *PLoS Med*. 2008; 5: e155. <https://doi.org/10.1371/journal.pmed.0050155> PMID: 18700811
34. Gan Y, Gong Y, Tong X, Sun H, Cong Y, Dong X, et al. Depression and the risk of coronary heart disease: a meta-analysis of prospective cohort studies. *BMC Psychiatry*. 2014; 14: 371. <https://doi.org/10.1186/s12888-014-0371-z> PMID: 25540022
35. Vancampfort D, Correll CU, Wampers M, Sienaert P, Mitchell AJ, De Herdt A, et al. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables. *Psychol Med*. 2014; 44: 2017–2028. <https://doi.org/10.1017/S0033291713002778> PMID: 24262678
36. Rotella F, Mannucci E. Depression as a Risk Factor for Diabetes: A Meta-Analysis of Longitudinal Studies. *J Clin Psychiatry*. 2013; 74: 31–37. <https://doi.org/10.4088/JCP.12r07922> PMID: 23419223
37. Scherrer JF, Xian H, Bucholz KK, Eisen SA, Lyons MJ, Goldberg J, et al. A Twin Study of Depression Symptoms, Hypertension, and Heart Disease in Middle-Aged Men. *Psychosom Med*. 2003; 65: 548–557. <https://doi.org/10.1097/01.psy.0000077507.29863.cb> PMID: 12883104
38. Kan C, Pedersen NL, Christensen K, Bornstein SR, Licinio J, MacCabe JH, et al. Genetic overlap between type 2 diabetes and depression in Swedish and Danish twin registries. *Mol Psychiatry*. 2016; 21: 903–909. <https://doi.org/10.1038/mp.2016.28> PMID: 27021822
39. Haljas K, Amare AT, Alizadeh BZ, Hsu Y-H, Mosley T, Newman A, et al. Bivariate Genome-Wide Association Study of Depressive Symptoms With Type 2 Diabetes and Quantitative Glycemic Traits: *Psychosom Med*. 2018; 80: 242–251. <https://doi.org/10.1097/PSY.0000000000000555> PMID: 29280852
40. Khandaker GM, Zuber V, Rees JMB, Carvalho L, Mason AM, Foley CN, et al. Shared mechanisms between coronary heart disease and depression: findings from a large UK general population-based cohort. *Mol Psychiatry*. 2020; 25: 1477–1486. <https://doi.org/10.1038/s41380-019-0395-3> PMID: 30886334

41. Clarke T-K, Obsteter J, Hall LS, Hayward C, Thomson PA, Smith BH, et al. Investigating shared aetiology between type 2 diabetes and major depressive disorder in a population based cohort. *Am J Med Genet B Neuropsychiatr Genet.* 2017; 174: 227–234. <https://doi.org/10.1002/ajmg.b.32478> PMID: 27480393
42. Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM, Rayner NW, et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. *Nat Genet.* 2018; 50: 1505–1513. <https://doi.org/10.1038/s41588-018-0241-6> PMID: 30297969
43. Hagenaars SP, Coleman JRI, Choi SW, Gaspar H, Adams MJ, Howard DM, et al. Genetic comorbidity between major depression and cardio-metabolic traits, stratified by age at onset of major depression. *Am J Med Genet B Neuropsychiatr Genet.* 2020; 183: 309–330. <https://doi.org/10.1002/ajmg.b.32807> PMID: 32681593
44. Howard DM, Adams MJ, Clarke T-K, Hafferty JD, Gibson J, Shirali M, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. *Nat Neurosci.* 2019; 22: 343–352. <https://doi.org/10.1038/s41593-018-0326-7> PMID: 30718901
45. Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh P-R, et al. An atlas of genetic correlations across human diseases and traits. *Nat Genet.* 2015; 47: 1236–1241. <https://doi.org/10.1038/ng.3406> PMID: 26414676
46. Pilling LC, Dudbridge F, Melzer D, Bowden J, Frayling TM. 188-LB: Type 2 Diabetes Is Genetically Correlated with Multiple Long-Term Conditions but These Correlations Are Only Partly Explained by BMI. *Diabetes.* 2021; 70: 188–LB. <https://doi.org/10.2337/db21-188-LB>
47. Torgersen K, Rahman Z, Bahrami S, Hindley GFL, Parker N, Frei O, et al. Shared genetic loci between depression and cardiometabolic traits. Flint J, editor. *PLOS Genet.* 2022; 18: e1010161. <https://doi.org/10.1371/journal.pgen.1010161> PMID: 35560157
48. Nikpay M, Goel A, Won H-H, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat Genet.* 2015; 47: 1121–1130. <https://doi.org/10.1038/ng.3396> PMID: 26343387
49. Grotzinger AD, Rhemtulla M, de Vlaming R, Ritchie SJ, Mallard TT, Hill WD, et al. Genomic structural equation modelling provides insights into the multivariate genetic architecture of complex traits. *Nat Hum Behav.* 2019; 3: 513–525. <https://doi.org/10.1038/s41562-019-0566-x> PMID: 30962613
50. Scott RA, Scott LJ, Mägi R, Marullo L, Gaulton KJ, Kaakinen M, et al. An Expanded Genome-Wide Association Study of Type 2 Diabetes in Europeans. *Diabetes.* 2017; 66: 2888–2902. <https://doi.org/10.2337/db16-1253> PMID: 28566273
51. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. *Nat Commun.* 2017; 8: 1826. <https://doi.org/10.1038/s41467-017-01261-5> PMID: 29184056
52. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics.* 2010; 26: 2336–2337. <https://doi.org/10.1093/bioinformatics/btq419> PMID: 20634204
53. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. *Bioinforma Oxf Engl.* 2011; 27: 1739–1740. <https://doi.org/10.1093/bioinformatics/btr260> PMID: 21546393
54. Kutmon M, Riutta A, Nunes N, Hanspers K, Willighagen EL, Bohler A, et al. WikiPathways: capturing the full diversity of pathway knowledge. *Nucleic Acids Res.* 2016; 44: D488–494. <https://doi.org/10.1093/nar/gkv1024> PMID: 26481357
55. Aguet F, Barbeira AN, Bonazzola R, Brown A, Castel SE, Jo B, et al. The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Genetics.* 2019 Oct. <https://doi.org/10.1101/787903>
56. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: Generalized Gene-Set Analysis of GWAS Data. Tang H, editor. *PLOS Comput Biol.* 2015; 11: e1004219. <https://doi.org/10.1371/journal.pcbi.1004219> PMID: 25885710
57. Choi SW O'Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale data. *GigaScience.* 2019; 8: giz082. <https://doi.org/10.1093/gigascience/giz082> PMID: 31307061
58. Bulik-Sullivan BK, Loh P-R, Finucane HK, Ripke S, Yang J, Patterson N, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet.* 2015; 47: 291–295. <https://doi.org/10.1038/ng.3211> PMID: 25642630
59. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. *eLife.* 2018; 7: e34408. <https://doi.org/10.7554/eLife.34408> PMID: 29846171
60. Mounier N, Kutalik Z. Bias correction for inverse variance weighting Mendelian randomization. *Genet Epidemiol.* 2023; gepi.22522. <https://doi.org/10.1002/gepi.22522> PMID: 37036286

61. Milaneschi Y, Lamers F, Peyrot WJ, Abdellaoui A, Willemsen G, Hottenga J-J, et al. Polygenic dissection of major depression clinical heterogeneity. *Mol Psychiatry*. 2016; 21: 516–522. <https://doi.org/10.1038/mp.2015.86> PMID: 26122587
62. Milaneschi Y, Lamers F, Peyrot WJ, Baune BT, Breen G, Dehghan A, et al. Genetic Association of Major Depression With Atypical Features and Obesity-Related Immunometabolic Dysregulations. *JAMA Psychiatry*. 2017; 74: 1214. <https://doi.org/10.1001/jamapsychiatry.2017.3016> PMID: 29049554
63. Badini I, Coleman JRI, Hagenaars SP, Hotopf M, Breen G, Lewis CM, et al. Depression with atypical neurovegetative symptoms shares genetic predisposition with immuno-metabolic traits and alcohol consumption. *Psychol Med*. 2022; 52: 726–736. <https://doi.org/10.1017/S0033291720002342> PMID: 32624019
64. Milaneschi Y, Lamers F, Penninx BWJH. Dissecting Depression Biological and Clinical Heterogeneity —The Importance of Symptom Assessment Resolution. *JAMA Psychiatry*. 2021; 78: 341. <https://doi.org/10.1001/jamapsychiatry.2020.4373> PMID: 33471038
65. Nagel M, Jansen PR, Stringer S, Watanabe K, de Leeuw CA, Bryois J, et al. Meta-analysis of genome-wide association studies for neuroticism in 449,484 individuals identifies novel genetic loci and pathways. *Nat Genet*. 2018; 50: 920–927. <https://doi.org/10.1038/s41588-018-0151-7> PMID: 29942085
66. Kichaev G, Bhatia G, Loh P-R, Gazal S, Burch K, Freund MK, et al. Leveraging Polygenic Functional Enrichment to Improve GWAS Power. *Am J Hum Genet*. 2019; 104: 65–75. <https://doi.org/10.1016/j.ajhg.2018.11.008> PMID: 30595370
67. Vujkovic M, Keaton JM, Lynch JA, Miller DR, Zhou J, Tcheandjieu C, et al. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. *Nat Genet*. 2020; 52: 680–691. <https://doi.org/10.1038/s41588-020-0637-y> PMID: 32541925
68. Howard DM, Adams MJ, Shiri M, Clarke T-K, Marioni RE, Davies G, et al. Genome-wide association study of depression phenotypes in UK Biobank identifies variants in excitatory synaptic pathways. *Nat Commun*. 2018; 9: 1470. <https://doi.org/10.1038/s41467-018-03819-3> PMID: 29662059
69. Thorp JG, Campos AI, Grotzinger AD, Gerring ZF, An J, Ong J-S, et al. Symptom-level modelling unravels the shared genetic architecture of anxiety and depression. *Nat Hum Behav*. 2021; 5: 1432–1442. <https://doi.org/10.1038/s41562-021-01094-9> PMID: 33859377
70. van der Harst P, Verweij N. Identification of 64 Novel Genetic Loci Provides an Expanded View on the Genetic Architecture of Coronary Artery Disease. *Circ Res*. 2018; 122: 433–443. <https://doi.org/10.1161/CIRCRESAHA.117.312086> PMID: 29212778
71. Koyama S, Ito K, Terao C, Akiyama M, Horikoshi M, Momozawa Y, et al. Population-specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci for coronary artery disease. *Nat Genet*. 2020; 52: 1169–1177. <https://doi.org/10.1038/s41588-020-0705-3> PMID: 33020668
72. Wu Y, Cao H, Baranova A, Huang H, Li S, Cai L, et al. Multi-trait analysis for genome-wide association study of five psychiatric disorders. *Transl Psychiatry*. 2020; 10: 209. <https://doi.org/10.1038/s41398-020-00902-6> PMID: 32606422
73. Klarin D, Zhu QM, Emdin CA, Chaffin M, Horner S, McMillan BJ, et al. Genetic analysis in UK Biobank links insulin resistance and transendothelial migration pathways to coronary artery disease. *Nat Genet*. 2017; 49: 1392–1397. <https://doi.org/10.1038/ng.3914> PMID: 28714974
74. Mahajan A, Wessel J, Willems SM, Zhao W, Robertson NR, Chu AY, et al. Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. *Nat Genet*. 2018; 50: 559–571. <https://doi.org/10.1038/s41588-018-0084-1> PMID: 29632382
75. Coleman JRI, Gaspar HA, Bryois J, Bipolar Disorder Working Group of the Psychiatric Genomics Consortium, Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, Breen G. The Genetics of the Mood Disorder Spectrum: Genome-wide Association Analyses of More Than 185,000 Cases and 439,000 Controls. *Biol Psychiatry*. 2020; 88: 169–184. <https://doi.org/10.1016/j.biopsych.2019.10.015> PMID: 31926635
76. Hyde CL, Nagle MW, Tian C, Chen X, Paciga SA, Wendland JR, et al. Identification of 15 genetic loci associated with risk of major depression in individuals of European descent. *Nat Genet*. 2016; 48: 1031–1036. <https://doi.org/10.1038/ng.3623> PMID: 27479909
77. Cross-Disorder Group of the Psychiatric Genomics Consortium. Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. *Cell*. 2019; 179: 1469–1482.e11. <https://doi.org/10.1016/j.cell.2019.11.020> PMID: 31835028
78. Qi G, Chatterjee N. Heritability informed power optimization (HIPO) leads to enhanced detection of genetic associations across multiple traits. *PLoS Genet*. 2018; 14: e1007549. <https://doi.org/10.1371/journal.pgen.1007549> PMID: 30289880

79. Koskeridis F, Evangelou E, Said S, Boyle JJ, Elliott P, Dehghan A, et al. Pleiotropic genetic architecture and novel loci for C-reactive protein levels. *Nat Commun*. 2022; 13: 6939. <https://doi.org/10.1038/s41467-022-34688-6> PMID: 36376304
80. Lee S-B, Choi J-E, Park B, Cha M-Y, Hong K-W, Jung D-H. Dyslipidaemia-Genotype Interactions with Nutrient Intake and Cerebro-Cardiovascular Disease. *Biomedicines*. 2022; 10: 1615. <https://doi.org/10.3390/biomedicines10071615> PMID: 35884923
81. Naitza S, Porcu E, Steri M, Taub DD, Mulas A, Xiao X, et al. A Genome-Wide Association Scan on the Levels of Markers of Inflammation in Sardinians Reveals Associations That Underpin Its Complex Regulation. Sabeti PC, editor. *PLoS Genet*. 2012; 8: e1002480. <https://doi.org/10.1371/journal.pgen.1002480> PMID: 22291609
82. Han X, Ong J-S, An J, Hewitt AW, Gharahkhani P, MacGregor S. Using Mendelian randomization to evaluate the causal relationship between serum C-reactive protein levels and age-related macular degeneration. *Eur J Epidemiol*. 2020; 35: 139–146. <https://doi.org/10.1007/s10654-019-00598-z> PMID: 31900758
83. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nat Genet*. 2011; 43: 333–338. <https://doi.org/10.1038/ng.784> PMID: 21378990
84. Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. *Nat Genet*. 2022; 54: 1803–1815. <https://doi.org/10.1038/s41588-022-01233-6> PMID: 36474045
85. Zhang H, Wheeler W, Hyland PL, Yang Y, Shi J, Chatterjee N, et al. A Powerful Procedure for Pathway-Based Meta-analysis Using Summary Statistics Identifies 43 Pathways Associated with Type II Diabetes in European Populations. *PLoS Genet*. 2016; 12: e1006122. <https://doi.org/10.1371/journal.pgen.1006122> PMID: 27362418
86. Lee JJ, Wedow R, Okbay A, Kong E, Maghziyan O, Zacher M, et al. Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. *Nat Genet*. 2018; 50: 1112–1121. <https://doi.org/10.1038/s41588-018-0147-3> PMID: 30038396
87. Vuckovic D, Bao EL, Akbari P, Lareau CA, Mousas A, Jiang T, et al. The Polygenic and Monogenic Basis of Blood Traits and Diseases. *Cell*. 2020; 182: 1214–1231.e11. <https://doi.org/10.1016/j.cell.2020.08.008> PMID: 32888494
88. Watanabe K, Jansen PR, Savage JE, Nandakumar P, Wang X, 23andMe Research Team, et al. Genome-wide meta-analysis of insomnia prioritizes genes associated with metabolic and psychiatric pathways. *Nat Genet*. 2022; 54: 1125–1132. <https://doi.org/10.1038/s41588-022-01124-w> PMID: 35835914
89. Wootton RE, Richmond RC, Stuijzand BG, Lawn RB, Sallis HM, Taylor GMJ, et al. Evidence for causal effects of lifetime smoking on risk for depression and schizophrenia: a Mendelian randomisation study. *Psychol Med*. 2020; 50: 2435–2443. <https://doi.org/10.1017/S0033291719002678> PMID: 31689377
90. Jansen PR, Watanabe K, Stringer S, Skene N, Bryois J, Hammerschlag AR, et al. Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional pathways. *Nat Genet*. 2019; 51: 394–403. <https://doi.org/10.1038/s41588-018-0333-3> PMID: 30804565
91. Demange PA, Malanchini M, Mallard TT, Biroli P, Cox SR, Grotzinger AD, et al. Investigating the genetic architecture of noncognitive skills using GWAS-by-subtraction. *Nat Genet*. 2021; 53: 35–44. <https://doi.org/10.1038/s41588-020-00754-2> PMID: 33414549
92. Said S, Pazoki R, Karhunen V, Vösa U, Ligthart S, Bodinier B, et al. Genetic analysis of over half a million people characterises C-reactive protein loci. *Nat Commun*. 2022; 13: 2198. <https://doi.org/10.1038/s41467-022-29650-5> PMID: 35459240
93. Hannou SA, Wouters K, Paumelle R, Staels B. Functional genomics of the CDKN2A/B locus in cardiovascular and metabolic disease: what have we learned from GWASs? *Trends Endocrinol Metab*. 2015; 26: 176–184. <https://doi.org/10.1016/j.tem.2015.01.008> PMID: 25744911
94. Xue A, Wu Y, Zhu Z, Zhang F, Kemper KE, Zheng Z, et al. Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes. *Nat Commun*. 2018; 9: 2941. <https://doi.org/10.1038/s41467-018-04951-w> PMID: 30054458
95. Middelberg RPS, Ferreira MAR, Henders AK, Heath AC, Madden PAF, Montgomery GW, et al. Genetic variants in LPL, OASL and TOMM40/APOE-C1-C2-C4 genes are associated with multiple cardiovascular-related traits. *BMC Med Genet*. 2011; 12: 123. <https://doi.org/10.1186/1471-2350-12-123> PMID: 21943158
96. Mahajan A, Spracklen CN, Zhang W, Ng MCY, Petty LE, Kitajima H, et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. *Nat Genet*. 2022; 54: 560–572. <https://doi.org/10.1038/s41588-022-01058-3> PMID: 35551307

97. Ligthart S, Vaez A, Vösa U, Stathopoulou MG, de Vries PS, Prins BP, et al. Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders. *Am J Hum Genet.* 2018; 103: 691–706. <https://doi.org/10.1016/j.ajhg.2018.09.009> PMID: 30388399
98. Ahola-Olli AV, Würtz P, Havulinna AS, Aalto K, Pitkänen N, Lehtimäki T, et al. Genome-wide Association Study Identifies 27 Loci Influencing Concentrations of Circulating Cytokines and Growth Factors. *Am J Hum Genet.* 2017; 100: 40–50. <https://doi.org/10.1016/j.ajhg.2016.11.007> PMID: 27989323
99. Ruderfer DM, Fanous AH, Ripke S, McQuillin A, Amdur RL, Schizophrenia Working Group of the Psychiatric Genomics Consortium, et al. Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia. *Mol Psychiatry.* 2014; 19: 1017–1024. <https://doi.org/10.1038/mp.2013.138> PMID: 24280982
100. Lauc G, Essafi A, Huffman JE, Hayward C, Knežević A, Kattila JJ, et al. Genomics meets glycomics—the first GWAS study of human N-Glycome identifies HNF1 α as a master regulator of plasma protein fucosylation. *PLoS Genet.* 2010; 6: e1001256. <https://doi.org/10.1371/journal.pgen.1001256> PMID: 21203500
101. Le Page C, Génin P, Baines MG, Hiscott J. Interferon activation and innate immunity. *Rev Immunogenet.* 2000; 2: 374–386. PMID: 11256746
102. El-Zayat SR, Sibaii H, Mannaa FA. Toll-like receptors activation, signaling, and targeting: an overview. *Bull Natl Res Cent.* 2019; 43: 187. <https://doi.org/10.1186/s42269-019-0227-2>
103. Leonard BE. The Concept of Depression as a Dysfunction of the Immune System. *Curr Immunol Rev.* 2010; 6: 205–212. <https://doi.org/10.2174/157339510791823835> PMID: 21170282
104. Figueroa-Hall LK, Paulus MP, Savitz J. Toll-Like Receptor Signaling in Depression. *Psychoneuroendocrinology.* 2020; 121: 104843. <https://doi.org/10.1016/j.psyneuen.2020.104843> PMID: 32911436
105. Martín-de-Saavedra MD, Budni J, Cunha MP, Gómez-Rangel V, Lorrio S, del Barrio L, et al. Nrf2 participates in depressive disorders through an anti-inflammatory mechanism. *Psychoneuroendocrinology.* 2013; 38: 2010–2022. <https://doi.org/10.1016/j.psyneuen.2013.03.020> PMID: 23623252
106. Mostafavi S, Battle A, Zhu X, Potash JB, Weissman MM, Shi J, et al. Type I interferon signaling genes in recurrent major depression: increased expression detected by whole-blood RNA sequencing. *Mol Psychiatry.* 2014; 19: 1267–1274. <https://doi.org/10.1038/mp.2013.161> PMID: 24296977
107. Milaneschi Y, Kappelmann N, Ye Z, Lamers F, Moser S, Jones PB, et al. Association of inflammation with depression and anxiety: evidence for symptom-specificity and potential causality from UK Biobank and NESDA cohorts. *Mol Psychiatry.* 2021; 26: 7393–7402. <https://doi.org/10.1038/s41380-021-01188-w> PMID: 34135474
108. Fioranelli M, Bottaccioli AG, Bottaccioli F, Bianchi M, Rovesti M, Rocchia MG. Stress and Inflammation in Coronary Artery Disease: A Review Psychoneuroendocrineimmunology-Based. *Front Immunol.* 2018; 9: 2031. <https://doi.org/10.3389/fimmu.2018.02031> PMID: 30237802
109. Christodoulidis G, Vittorio TJ, Fudim M, Lerakis S, Kosmas CE. Inflammation in Coronary Artery Disease. *Cardiol Rev.* 2014; 22: 279–288. <https://doi.org/10.1097/CRD.000000000000006> PMID: 24441047
110. Zhou T, Hu Z, Yang S, Sun L, Yu Z, Wang G. Role of Adaptive and Innate Immunity in Type 2 Diabetes Mellitus. *J Diabetes Res.* 2018; 2018: 1–9. <https://doi.org/10.1155/2018/7457269> PMID: 30533447
111. Minichino Amedeo, Francesco Saverio Bersani Guido Trabucchi, Albano Gabriella, Primavera Martina, Roberto Delle Chiaie, et al. The role of cerebellum in unipolar and bipolar depression: a review of the main neurobiological findings. *Riv Psichiatr.* 2014 [cited 13 Apr 2023]. <https://doi.org/10.1708/1551.16907> PMID: 25000888
112. Hilber P, Cendelin J, Le Gall A, Machado M-L, Tuma J, Besnard S. Cooperation of the vestibular and cerebellar networks in anxiety disorders and depression. *Prog Neuropsychopharmacol Biol Psychiatry.* 2019; 89: 310–321. <https://doi.org/10.1016/j.pnpbp.2018.10.004> PMID: 30292730
113. Kendler KS, Gardner CO, Fiske A, Gatz M. Major Depression and Coronary Artery Disease in the Swedish Twin Registry: Phenotypic, Genetic, and Environmental Sources of Comorbidity. *Arch Gen Psychiatry.* 2009; 66: 857. <https://doi.org/10.1001/archgenpsychiatry.2009.94> PMID: 19652125
114. Dalton VS, Kolshus E, McLoughlin DM. Epigenetics and depression: return of the repressed. *J Affect Disord.* 2014; 155: 1–12. <https://doi.org/10.1016/j.jad.2013.10.028> PMID: 24238955
115. Bellou V, Belbasis L, Tzoulaki I, Evangelou E. Risk factors for type 2 diabetes mellitus: An exposure-wide umbrella review of meta-analyses. *Nerurkar PV, editor. PLOS ONE.* 2018; 13: e0194127. <https://doi.org/10.1371/journal.pone.0194127> PMID: 29558518
116. Hajar R. Risk factors for coronary artery disease: Historical perspectives. *Heart Views.* 2017; 18: 109. https://doi.org/10.4103/HEARTVIEWS.HEARTVIEWS_106_17 PMID: 29184622